Table 5.
Comparison between the WHO PMWC list and SA STG/EMLs
| Priority life‐saving medicines for children under five years of age for major causes of mortality and morbidity, palliative care and child survival | ||||||||
|---|---|---|---|---|---|---|---|---|
| Condition | Drug | Formulation and Strength | PHC 2008 | ADULT 2012 | PAED 2013 | |||
| Mol | DF | Mol | DF | Mol | DF | |||
| Pneumonia | Amoxicillin | dispersible, scored tablets 250 mg and 500 mg or equivalent flexible oral solid dosage form | √ | X | √ | X | ||
| Pneumonia | Ampicillin | powder for injection 500 mg and 1 g | X | √ | IV | |||
| Pneumonia | Ceftriaxone | powder for injection 250 mg and 1 g | √ | IV | √ | IV | ||
| Pneumonia | Gentamicin | injection 40 mg/ml; 20 mg/ml | X | √ | IV | |||
| Pneumonia | Oxygen | medicinal gas | √ | √ | ||||
| Diarrhoea | Oral rehydration salts (ORS): | sachets of 200 ml; 500 ml and 1 l, appropriate flavour | √ | sachets | √ | sachets | ||
| Diarrhoea | Zinc | 20 mg scored dispersible tablet or equivalent flexible oral solid dosage form | X | X | ||||
| Malaria | Artemesinin combination therapy (ACT) | dispersible tablet or flexible oral solid dosage form and dose optimized | X | X | ||||
| Malaria | Artesunate | rectal and injection dosage forms 50–200 mg | X | X | ||||
| Neonatal sepsis | Ampicillin | powder fir injection 250 mg and 500 mg | X | √ | IV | |||
| Neonatal sepsis | Ceftriaxone | powder for injection 250 mg and 500 mg | √ | IV | √ | IV | ||
| Neonatal sepsis | Gentamicin | injection 40 mg/ml; 20 mg/ml | X | √ | IV | |||
| Neonatal sepsis | Procaine benzylpenicillin | powder for injection 1 g | X | √ | IM | |||
| HIV | Standard regimen for first-line antiretroviral treatment | 1 NNRTI + 2 NRTIs e.g. lamivudine + nevirapine + zidovudine - tablet 30 mg + 50 mg + 60 mg; 150 mg + 200 mg + 300 mg | √ | oral | √ | oral | ||
| Vitamin A deficiency | Vitamin A | capsule 100 000 IU strength; 200 000 IU strength | √ | capsule | √ | capsule | ||
| Palliative care/Pain | Morphine | granules 20 mg, 30 mg, 60 mg, 100 mg, 200 mg; injection 10 mg/ml, oral liquid 10 mg/5 ml, | √ | IV | √ | Oral liquid | ||
| Palliative care/Pain | Paracetamol | variable flexible oral solid dosage forms | √ | x | √ | x | ||
| Vaccines | BCG | √ | √ | |||||
| Vaccines | Hepatitis B | √ | √ | |||||
| Vaccines | Polio | √ | √ | |||||
| Vaccines | DTP | √ | X | |||||
| Vaccines | Haemophilus influenze Type b | √ | X | |||||
| Vaccines | Pneumococcal (conjugate) | X | √ | |||||
| Vaccines | Rotavirus | X | X | |||||
| Vaccines | Measles | √ | √ | |||||
| Vaccines | Rubella | X | X | |||||
| Vaccines | HPV | X | X | |||||
| Vaccines | Japanese Encephalitis | X | X | |||||
| Vaccines | Yellow fever | X | X | |||||
| Vaccines | Tick Borne encephalitis | X | X | |||||
| Vaccines | Typhoid | X | X | |||||
| Vaccines | Cholera | X | X | |||||
| Vaccines | Meningococcal | X | X | |||||
| Vaccines | Hepatitis A | X | X | |||||
| Vaccines | Rabies | √ | √ | |||||
| Vaccines | Mumps | X | X | |||||
| Vaccines | Influenze (Inactivated) | √ | √ | |||||
| Priority life‐saving medicines for women for major causes of sexual and reproductive health related mortality and morbidity | ||||||||
| Post-partum haemorrhage | Oxytocin | injection 10 IU in 1‐ml ampoule | √ | √ | ||||
| Post-partum haemorrhage | Misoprostol | tablet 200 micrograms (when oxytocin is not available or cannot safely be used) | √ | √ | ||||
| Post-partum haemorrhage | Sodium chloride | injectable solution 0.9% isotonic or | √ | √ | ||||
| Post-partum haemorrhage | Sodium lactate compound | injectable solution (Ringer’s lactate) for infusion | √ | X | ||||
| Severe pre‐eclampsia/eclampsia | Magnesium sulfate | injection 500 mg/ml in 10‐ml ampoule | √ | √ | ||||
| Severe pre‐eclampsia/eclampsia | Calcium gluconate injection (for treatment of magnesium toxicity) | 100 mg/ml in 10‐ml ampoule | √ | √ | ||||
| Severe pre‐eclampsia/eclampsia | Hydralazine | powder for injection 20 mg (hydrochloride) in ampoule or tablet 25 mg; 50 mg (hydrochloride) | X | √ | ||||
| Severe pre‐eclampsia/eclampsia | Methyldopa | tablet 250 mg | √ | √ | ||||
| Maternal sepsis | Ampicillin | powder for injection 500 mg; 1 g | X | √ | ||||
| Maternal sepsis | Gentamicin | injection 40 mg/ml in 2‐ml vial | X | √ | ||||
| Maternal sepsis | Metronidazole | injection 500 mg in 100‐ml vial | X | √ | ||||
| Abortion/miscarriage | Misoprostol | tablet 200 micrograms | √ | √ | ||||
| Abortion/miscarriage | Mifepristone + misoprostol | tablet 200 mg + tablet 200 micrograms (where permitted under national law) | X | √ | ||||
| STIs | Azithromycin | capsule 250 mg; 500 mg or oral liquid 200 mg/5 ml | X | X | ||||
| STIs | Cefixime | capsule 400 mg | √ | √ | ||||
| STIs | Benzathine Benzylpenicillin | powder for injection 900 mg benzylpenicillin in 5 ml vial; 1,44 g benzylpenicillin in 5 ml vial | √ | √ | ||||
| Preterm labour | Nifedipine | immediate release capsule 10 mg | √ | √ | ||||
| preterm labour (foetal lung maturity) | Dexamethasone | injection 4 mg dexamethasone phosphate (as disodium salt) in 1‐ml ampoule or | X | √ | ||||
| preterm labour (foetal lung maturity) | Betamethasone | injection 6 mg/ml (3 mg/ml betamethasone sodium phosphate + 3 mg/ml betamethasone acetate) in an aqueous vehicle | √ | √ | ||||
| Maternal Malaria | Artesunate | parenteral | X | X | ||||
| Maternal Malaria | Artemether | parenteral | X | X | ||||
| Maternal Malaria | Quinine | parenteral | √ | √ | ||||
| Maternal HIV/AIDS | AZT; 3TC; EFV; NVP; EFV; TDF; FTC; ABC; LPV | Doses not stipulated | √ | √ | ||||
| Prevention of tetanus from MTC | Tetanus vaccine | √ | √ | |||||
| Contraception | Oral contraceptives such as ethinylestradiol + levonorgestrel | tablet 30 micrograms + 150 micrograms; | √ | √ | ||||
| Contraception | levonorgestrel | 750 micrograms (pack of 2); | √ | X | ||||
| Contraception | Injectable: estradiol cypionate + medroxyprogesterone acetate | injection 5 mg + 25 mg or | X | X | ||||
| Contraception | medroxyprogesterone acetate | depot injection 150 mg/ml in 1‐ml vial or | √ | X | ||||
| Contraception | norethisterone enantate | 200 mg/ml in 1‐ml ampoule | √ | X | ||||
| Contraception | implantable: levonorgestrel-releasing implant | 150 mg total | X | X | ||||
| Contraception | intrauterine devices and barrier methods of contraception | copper-containing devices; condoms; diaphragms | √ | X | ||||
Mol Molecule, DF Dosage Form